Cian Healthcare
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Key Insights
Strengths
2- Company has reduced debt.
- Promoter holding has increased by 67.9% over last quarter.
Weaknesses
6- Stock is trading at 8.21 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -17.4% over past five years.
- Company has a low return on equity of -18.6% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 163 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 5 | 1 | 13 |
| Oscillators | Strong Bearish | 5 | 1 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Strong Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 99.66
- Bearish
- MACD (12,26,9)
- 3.99
- Bullish
- SMA (50)
- 19.89
- Bullish
- SMA (200)
- 8.50
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | −17.66% |
|---|---|
| 3Y | −25.97% |
| 1Y | −9.68% |
Net profit
| 5Y | Turned to loss |
|---|---|
| 3Y | Turned to loss |
| 1Y | Loss narrowed by ₹3 Cr |
Operating cash flow
| 5Y | Turned negative |
|---|---|
| 3Y | Turned negative |
| 1Y | Turned negative |
Operating margin· change in pp
| 5Y | −41.22 pp |
|---|---|
| 3Y | −43.84 pp |
| 1Y | −2.42 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2020 | ₹57.00 Cr |
|---|---|
| Mar 2021 | ₹74.00 Cr |
| Mar 2022 | ₹78.00 Cr |
| Mar 2023 | ₹69.00 Cr |
| Mar 2024 | ₹62.00 Cr |
| Mar 2025 | ₹31.00 Cr |
| Mar 2026 | ₹28.00 Cr |
Net profit by year
| Mar 2020 | −₹4.00 Cr |
|---|---|
| Mar 2021 | ₹0.00 Cr |
| Mar 2022 | −₹6.00 Cr |
| Mar 2023 | ₹2.00 Cr |
| Mar 2024 | ₹1.00 Cr |
| Mar 2025 | −₹26.00 Cr |
| Mar 2026 | −₹23.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 28 | 39 | 35 | 47 | 31 | 38 | 31 | 33 | 62 | 19 | 12 | 17 |
| Expenses | 26 | 23 | 34 | 28 | 44 | 30 | 32 | 24 | 28 | 51 | 20 | 17 | 20 |
| Operating Profit | 3 | 4 | 5 | 7 | 3 | 1 | 5 | 7 | 4 | 11 | −1 | −5 | −3 |
| OPM % | 10% | 15% | 13% | 20% | 7% | 2.9% | 14% | 22% | 14% | 18% | −8% | −44% | −18% |
| Other Income | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | −12 | 0 | −13 |
| Interest | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 6 | 2 | 1 | 0 |
| Depreciation | 2 | 3 | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 2 | 2 | 2 |
| PBT | −2 | −2 | −1 | 2 | −2 | −4 | 0 | 2 | −1 | 0 | −18 | −8 | −18 |
| Tax % | 0% | 17% | 23% | 28% | 7% | −13% | −167% | 14% | 37% | −400% | 0% | 0% | 0% |
| Net Profit | −2 | −2 | −1 | 1 | −2 | −4 | 0 | 2 | −1 | 0 | −18 | −8 | −18 |
| EPS (₹) | −0.86 | −0.75 | −0.46 | 0.48 | −0.72 | −1.54 | 0.19 | 0.62 | −0.59 | 0.1 | −7.3 | −3.09 | −7.19 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 57 | 74 | 78 | 69 | 62 | 31 | 28 |
| Expenses | 50 | 62 | 74 | 56 | 51 | 37 | 35 |
| Operating Profit | 7 | 12 | 4 | 13 | 11 | −7 | −7 |
| OPM % | 13% | 16% | 6% | 19% | 18% | −21% | −23% |
| Other Income | 1 | 0 | 0 | 1 | 0 | −12 | −12 |
| Interest | 7 | 8 | 7 | 6 | 6 | 3 | 1 |
| Depreciation | 4 | 3 | 4 | 5 | 5 | 4 | 4 |
| PBT | −4 | 1 | −6 | 2 | 0 | −26 | −23 |
| Tax % | 7% | 91% | −8% | −2% | −1600% | 0% | 0% |
| Net Profit | −4 | 0 | −6 | 2 | 1 | −26 | −23 |
| EPS (₹) | −1.62 | 0.02 | −2.21 | 0.81 | 0.34 | −10.39 | −9.32 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 35 | 35 | 30 | 32 | 33 | 7 | −16 |
| Borrowings | 73 | 71 | 63 | 61 | 56 | 55 | 29 |
| Other Liabilities | 25 | 28 | 47 | 42 | 47 | 69 | 24 |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 156 | 62 |
| Fixed Assets | 39 | 37 | 50 | 45 | 39 | 35 | 32 |
| CWIP | 25 | 26 | 13 | 14 | 15 | 15 | 6 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 | 0 |
| Other Assets | 87 | 90 | 98 | 97 | 102 | 101 | 23 |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 156 | 62 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | −7 | 6 | 9 | 5 | 12 | 21 | −1 |
| Investing | −27 | 3 | 1 | 3 | −1 | 0 | 13 |
| Financing | 36 | −10 | −11 | −7 | −10 | −4 | −28 |
| Net Cash Flow | 1 | −1 | −1 | 0 | 0 | 17 | −17 |
| Free Cash Flow | −26 | 4 | 4 | 4 | 11 | 20 | 7 |
| CFO/EBITDA | −99 | 49 | 197 | 37 | 106 | −315 | 22 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 128 | 94 | 125 | 140 | 121 | 206 | 163 |
| Inventory Days | 214 | 277 | 300 | 400 | 486 | 420 | 82 |
| Days Payable | 176 | 186 | 270 | 296 | 371 | 671 | 219 |
| Cash Conversion Cycle | 166 | 185 | 155 | 244 | 236 | −45 | 26 |
| Working Capital Days | 15 | 16 | 38 | 41 | 26 | −729 | −96 |
| ROCE % | — | 7% | 0% | 7% | 5% | −11% | −15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Cian Healthcare insights
62 extracted metrics across FY16–FY26.
Documents
- 29 Oct 2025
- 30 Sep 2025
- 28 Mar 2025
- 15 Oct 2024
- 18 Jul 2023
- 22 Sep 2026
Frequently Asked Questions about Cian Healthcare
What does Cian Healthcare Ltd do?
Where is Cian Healthcare Ltd (CHCL) listed?
Which sector does Cian Healthcare Ltd belong to?
What is the 52-week high and low of Cian Healthcare Ltd?
Company Information
Cian Healthcare Ltd is a BSE-SME listed pharmaceutical-formulations manufacturer with own /franchise brands, third-party manufacturing, institutional/government supply and exports. It makes tablets, capsules, soft-gels, liquid orals, ointments/creams, sachets and cosmetics across gynaecology, haematinic, cardio-diabetic, orthopaedic, paediatric, derma-cosmetic, antibiotic, CNS, vitamins and nutrients. The company exited CIRP under new promoter control in FY26
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/542678.md for Cian Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.